Biostar Pharmaceuticals, Inc.
BSPM
BSPM was delisted on the 18th of September, 2018.
7 hedge funds and large institutions have $780K invested in Biostar Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
33% less capital invested
Capital invested by funds: $1.17M → $780K (-$391K)
36% less funds holding
Funds holding: 11 → 7 (-4)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$20.3K |
| 2 |
Morgan Stanley
New York
|
+$13.6K |
| 3 |
Renaissance Technologies
New York
|
+$12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$71K |
| 2 |
EGA
Eagle Global Advisors
Houston,
Texas
|
-$33K |
| 3 |
Jane Street
New York
|
-$21K |
| 4 |
Two Sigma Investments
New York
|
-$16K |
| 5 |
SIM
Spark Investment Management
New York
|
-$7.33K |
BSPM Hedge Fund Activity: Q4 2014 in Review
7 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q4 2014, worth a combined $780K — down 33% from $1.17M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BSPM and 2 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $20.3K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $71K sold.
- 7 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q4 2014, down from 11 in Q3 2014.
- Funds reported $780K of Biostar Pharmaceuticals, Inc. stock for Q4 2014, down 33% quarter-over-quarter.
- 2 funds opened new Biostar Pharmaceuticals, Inc. positions in Q4 2014 and 5 closed out, a net change of -3 holders.
- The largest Biostar Pharmaceuticals, Inc. buyer in Q4 2014 was Citadel Advisors, an estimated $20.3K added.
- The largest Biostar Pharmaceuticals, Inc. seller in Q4 2014 was Bridgeway Capital Management, an estimated $71K sold.
Based on aggregated 13F filings for Q4 2014.